Abstract
• Background: Systemic adverse effects of ocular timolol therapy are due to absorption of the drug from the eye into the systemic circulation. Elderly patients are frequently more susceptible to side effects than younger patients. This study was conducted to evaluate the plasma kinetics and antagonist activity of ocular timolol in elderly patients. • Methods: Plasma kinetics and antagonist activity of timolol were studied in 12 patients scheduled for extracapsular cataract extraction and intraocular lens implantation. The patients received 40 μl of 0.25% timolol into the lower cul-de-sacs of each eye. Blood samples were collected over a period of 12 h and plasma concentrations of timolol were analyzed using a radioreceptor assay. The corresponding ex vivo β1- and β2-receptor occupancies were calculated using radioligand binding techniques. • Results: Timolol was absorbed rapidly into the systemic circulation and occupied on average up to 68% of β1-receptors and up to 87% of β2-receptors. The β1- and β2-receptor occupancy decreased slowly and was on average 38% and 64%, respectively, 12 h after the single dose. The calculated mean area under concentration-time curve of timolol in plasma was 10.28 ng/ml per hour and the mean half-life was 4.8 h. Both values were about twice as high as those found in healthy young volunteers following an intravenous 0.25-mg dose of timolol. • Conclusions: In elderly patients the β-receptor antagonist effect of ocular timolol after a single dose is strong and long-lasting. This finding may explain the frequent reported systemic side effects of ophthalmic timolol.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Huupponen R, Kaila T, Lahdes K, Salminen L, Iisalo E (1991) Systemic absorption of ocular timolol in poor and extensive metabolizers of debrisoquine. J Ocul Pharmacol 7:183–187
Kaila T (1991) A sensitive radioligand binding assay for timolol in plasma. J Pharm Sci 80:296–299
Kaila T, Salminen L, Huupponen R (1985) Systemic absorption of topically applied ocular timolol. J Ocul Pharmacol 1:79–83
Kaila T, Huupponen R, Karhuvaara S, Havula P, Scheinin M, Iisalo E, Salminen L (1991) Beta-blocking effects of timolol at low plasma concentrations. Clin Pharmacol Ther 49:53–58
Kaila T, Karhuvaara S, Huupponen R, Iisalo E (1993) The analysis of plasma kinetics and β-receptor binding and -blocking activity of timolol following its small intravenous dose. Int J Clin Pharmacol Ther Toxicol 31:351–357
McMahon CD, Shaffer RN, Hoskins HDJ, Hetherington JJ (1979) Adverse effects experienced by patients taking timolol. Am J Ophthalmol 88:736–738
Passo MS, Pahner EA, Van Buskirk EM (1984) Plasma timolol in glaucoma patients. Ophthalmology 91:1361–1363
Van Buskirk EM (1980) Adverse reactions from timolol administration. Ophthalmology 87:447–450
Vuori M-L, Ali-Melkkilä T, Kaila T, Iisalo E, Saari KM (1993) β1- and β2-antagonist activity of topically applied betaxolol and timolol in the systemic circulation. Acta Ophthalmol 71:682–685
Vuori M-L, Ali-Melkkilä T (1993) The effect of betaxolol and timolol on postoperative intraocular pressure. Acta Ophthalmol 71:458–462
Wellstein A, Palm D, Pitcshner HF, Belz G-G (1985) Receptor-binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol 29:131–147
Wellstein A, Palm D, Belz G-G, Butzer R, Polsak R, Pett B (1987) Reduction of exercise tachycardia in man after propranolol, atenolol, and bisoprolol in comparison to β-adrenoceptor occupancy. Eur Heart J 8 [Suppl M]:3–8
Williams LT, Lefkowitz RJ (1978) Radioligand binding studies in adrenergic pharmacology. Raven Press, New York, pp 27–41
Zimmerman TJ, Kaufman HE (1977) Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 95:601–604
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vuori, ML., Kaila, T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefe's Arch Clin Exp Ophthalmol 233, 131–134 (1995). https://doi.org/10.1007/BF00166604
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00166604